News
Astellas pays $285m for Audax cancer drug, and other deals
Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
News
Lilly's triple G overpowers Ozempic in diabetes trial
Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.
News
Ferring builds in reproductive health via $1.38bn Gameto buy
Switzerland's Ferring Pharma has reached an agreement to buy US fertility start-up Gameto for up to $1.38bn.
News
Anthropic sets out its biopharma ambitions in IPO doc
Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
News
ESMO26: Ris-rez offers hope of osteosarcoma breakthrough
There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
